SCHEMBL5875840

SCHEMBL5875840

N#Cc1c(O)cccc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
MAPT P10636 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
SOS2 Q07890 1/20 0.37
TTR P02766 1/20 0.37
ALB P02768 1/20 0.37
CXCR2 P25025 3/20 0.36
CXCR1 P25024 2/20 0.36
DYRK1A Q13627 1/20 0.36
LMNA P02545 3/20 0.36
EGFR P00533 2/20 0.36
CA2 P00918 2/20 0.36
FYN P06241 2/20 0.36
MMP9 P14780 2/20 0.36
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1343169 0.83 DYRK1A (0.42) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL2285228 0.83 ALDH1A1 (0.50) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL1285613 0.74 ALDH1A1 (0.43) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL769669 0.74 DYRK1A (0.46) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL30473828 0.74 ALDH1A1 (0.43) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL2336330 0.73 TSHR (0.50) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL1622559 0.73 ALOX15 (0.48) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL9329818 0.73 L3MBTL1 (0.47) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL11876975 0.73 CYP1A2 (0.50) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL6874358 0.73 ALDH1A1 (0.41) ALDH1A1MAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724542-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES Merck Patent GmbH (DE) 2026-04-15 EP disclosed
US-20260047265-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2026-02-12 US disclosed
EP-4573099-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES Merck Patent GmbH (DE) 2025-06-25 EP disclosed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 US disclosed
CN-119698419-A Material for organic electroluminescent device 默克专利有限公司 2025-03-25 CN disclosed
WO-2024251699-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2024-12-12 WO disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 EP disclosed
US-12043624-B2 Organic compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2024-07-23 US disclosed
US-20240199587-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-06-20 US disclosed
EP-4326714-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-02-28 EP disclosed
US-7087631-B2 Aryltetrazole compounds, and compositions thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2006-08-08 US disclosed
US-7078423-B2 5-Aryltetrazole compounds, compositions thereof, and uses therefor INOTEK PHARMACEUTICALS CORPORATION (US) 2006-07-18 US disclosed
US-20060135519-A2 5-ARYLTETRAZOLE COMPOUNDS AND COMPOSITIONS THEREOF NIVOROZHKIN ALEXANDER 2006-06-22 US disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
US-20050159418-A1 5-Aryltetrazoles compounds and compositions thereof NIVOROZHKIN ALEX (US) 2005-07-21 US disclosed
US-20050159467-A1 5-Aryltetrazole compounds and uses thereof NIVOROZHKIN ALEX (US) 2005-07-21 US disclosed
EP-1542980-A1 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR Inotek Pharmaceuticals Corporation (US) 2005-06-22 EP disclosed
US-20040116423-A1 5-Aryltetrazole compounds, compositions thereof, and uses therefor INOTEK PHARMACEUTICALS CORPORATION 2004-06-17 US disclosed
WO-2004009563-A1 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR INOTEK PHARMACEUTICALS CORPORATION (US) 2004-01-29 WO disclosed
US-20040019208-A1 5-Aryltetrazole Compounds, compositions thereof, and uses therefor INOTEK PHARMACEUTICALS CORPORATION 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043624-B2 Organic compound, light-emitting element, light-emitting device, electronic device, and lighting device CCNE2, NFE2L2, AOX1 ALDH1A1 134/4885MAPT 2611/4885MEN1 3330/4885
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 ALDH1A1 2415/4885MAPT 2339/4885MEN1 1285/4885
US-20240199587-A1 HETEROCYCLIC COMPOUNDS CYP1B1, CYP1A1, CYP4B1 ALDH1A1 295/4885MAPT 3552/4885MEN1 176/4885
US-20260047265-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES LEF1, DDT, MLLT1 ALDH1A1 253/4885MAPT 3943/4885MEN1 2440/4885
US-20060135519-A2 5-ARYLTETRAZOLE COMPOUNDS AND COMPOSITIONS THEREOF CASP5, NOX5, IL5 ALDH1A1 271/4885MAPT 659/4885MEN1 4780/4885
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 ALDH1A1 411/4885MAPT 2210/4885MEN1 2422/4885
US-20050159467-A1 5-Aryltetrazole compounds and uses thereof NLRP3, XDH, CASP5 ALDH1A1 234/4885MAPT 577/4885MEN1 4799/4885
US-20040019208-A1 5-Aryltetrazole Compounds, compositions thereof, and uses therefor CASP5, NLRP3, LITAF ALDH1A1 944/4885MAPT 1818/4885MEN1 3398/4885
US-20050159418-A1 5-Aryltetrazoles compounds and compositions thereof NLRP3, CASP5, CASP3 ALDH1A1 281/4885MAPT 479/4885MEN1 4817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.